drugset / Trial / NCT00374348
Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)
Completed
10 enrolled
Jamaica Hospital Medical Center
Bristol-Myers Squibb · collabDepartment of Psychiatry, Jamaica Hospital Medical Center · collabResearch Division · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the effectiveness of flexible doses (15-30mg) of Aripiprazole in the treatment of patients with schizophrenia and co-morbid symptoms of OCD in the outpatient setting. The overall effectiveness of Aripiprazole will be evaluated by use of the Brief Psychiatric Rating Scale(BPRS), Yale-Brown OCD scale and Clinical Global Impression-Improvement(CGI-I) scale.
Timeline
- Start
- 2005-03
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 10 mg | — |
| Subject | Aripiprazole | Other / unclassified | 15 mg | — |
| Subject | Aripiprazole | Other / unclassified | 20 mg | — |
| Subject | Aripiprazole | Other / unclassified | 30 mg | — |